Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
A EliasK H Antman

Abstract

In this phase II trial, 105 eligible patients with no prior chemotherapy and advanced sarcoma received doxorubicin, ifosfamide, and dacarbazine (DTIC) with mesna uroprotection (MAID). Starting doses of these drugs were 60, 7,500, and 900 mg/m2 divided over 72 hours by continuous infusion, respectively. Mesna was given for 84 to 96 hours at 2,500 mg/m2/d. Myelosuppression was dose limiting, causing the only toxic death (sepsis). Nonhematologic toxicity consisted predominantly of anorexia and vomiting. Severe mucositis, macroscopic hematuria, renal tubular acidosis, renal failure, and CNS toxicity occurred in less than 5% of cycles. No cardiotoxicity was detected. The overall response rate (10% complete response [CR]) was 47% (95% confidence intervals, 5% to 18% and 37% to 57%, respectively). Most responses (approximately 70%) were observed within two cycles. Median times to progression were 10 and 9 months, respectively. Histologic high tumor grade, lesions less than 5 cm, and less than 1 year from diagnosis to study entry correlated with the probability of response. The median survival was 16 months. Time from diagnosis to study entry, performance status, and extent of disease, but not histologic grade, correlated with survival...Continue Reading

Associated Clinical Trials

Citations

Jan 1, 1992·Cancer Chemotherapy and Pharmacology·T A WiklundI Elomaa
Jan 1, 1991·Journal of Cancer Research and Clinical Oncology·T M LoefflerT U Hausamen
Jan 1, 1993·Journal of Neuro-oncology·J de VriesW Hinkelbein
Feb 1, 1996·American Journal of Clinical Oncology·A MichelottiP Conte
Dec 1, 1996·Journal of Surgical Oncology·A A Valle, W G Kraybill
Jul 14, 1999·Seminars in Surgical Oncology·B P WhooleyW G Kraybill
Jan 26, 2005·Cancer Control : Journal of the Moffitt Cancer Center·T Christopher Windham, Peter W T Pisters
Oct 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Justin D FloydMichael C Perry
Mar 25, 2009·Expert Opinion on Drug Safety·Lauren HanlyGideon Koren
Jun 19, 2013·Current Treatment Options in Oncology·Alessandro Gronchi, Paolo G Casali
Oct 28, 2016·Cancer Chemotherapy and Pharmacology·Michael J Nathenson, Edward Sausville
Jul 20, 2016·Cancer·Ravin Ratan, Shreyaskumar R Patel
Jul 17, 2018·Oncology Letters·Argyrios IoannidisNikolaos Economou
Sep 1, 1994·Seminars in Surgical Oncology·J H Edmonson
Oct 2, 2002·Current Oncology Reports·Janice N CormierPeter W T Pisters
Jun 11, 2005·Cancer Investigation·Charles D Blanke, Christopher L Corless
Nov 30, 2006·Cancer·Akira KawaiUNKNOWN Japanese Musculoskeletal Oncology Group
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Massimo LopezSilvia Carpano
Apr 20, 2005·Journal of Pediatric Hematology/oncology·Karen H Albritton, R Lor Randall
Aug 6, 2009·Journal of Korean Medical Science·Seong Hoo ChoiGilho Lee
Oct 4, 2011·Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology·Ryo YamashitaIchiro Ito
Sep 14, 2012·Case Reports in Medicine·Yasutaka MurahashiToshihiko Yamashita
May 29, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Yoon Soo KyungGilho Lee
Jan 17, 2013·Cancer Investigation·Igor MatushanskyAlfred I Neugut
Oct 19, 2013·American Journal of Clinical Oncology·Adarsh Vijay, Lakshmi Ram
Nov 15, 2014·British Journal of Clinical Pharmacology·Lauren N FaughtKoren Gideon
Apr 14, 2016·Oncology Letters·Po-Jen HsiaoLi-Yuan Bai
Aug 6, 2017·The Annals of Pharmacotherapy·Benjamin J Andrick, Arpita Gandhi
Jan 1, 1991·Journal of Cancer Research and Clinical Oncology·A D EliasE Frei
Feb 1, 1997·Acta Orthopaedica Scandinavica. Supplementum·T A Alvegård, G Saeter
Mar 10, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·G. CiaravinoJ. A. Roberts

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.